Poor
Needs Revision
Patient Risk:
Medium
Summary
Some claims match the provided label excerpt (complete cure, mycologic cure, dosing duration/percent ranges), but multiple claims are unsupported or conflict with label excerpt details, and several safety/context claims are not supported by the provided prescribing information.
Category Scores
Accurate Statements
Jublia is indicated for topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.
Indications and Usage: “indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.” (Section 1)
In the provided label excerpt, complete cure rates assessed at Week 52 (4 weeks after completion) include 17.8% (Trial 1) and 15.2% (Trial 2).
Clinical Studies (Table 2): Trial 1 Complete Cure 17.8%; Trial 2 Complete Cure 15.2%; complete cure defined as 0% clinical involvement plus negative KOH and negative culture; assessed at Week 52.
In the provided label excerpt, mycologic cure rates assessed at Week 52 include 55.2% (Trial 1) and 53.4% (Trial 2).
Clinical Studies (Table 2): Trial 1 Mycologic Cure 55.2%; Trial 2 Mycologic Cure 53.4%; mycologic cure defined as negative KOH and negative culture.
Jublia is applied once daily for 48 weeks using the integrated flow-through brush applicator, and should cover the toenail/undersurface/adjacent structures as described.
Dosage and Administration: “Apply JUBLIA to affected toenails once daily for 48 weeks, using the integrated flow-through brush applicator… ensure the toenail… and the undersurface of the toenail plate, are completely covered.”
Unsupported Statements
Jublia (efinaconazole 10% topical solution) treats toenail fungus (onychomycosis) by inhibiting fungal growth.
The provided label excerpt does not state “inhibiting fungal growth” as the mechanism or describe that specific phrasing; it only provides that it is an azole antifungal (Mechanism of Action section not describing inhibition of fungal growth in the excerpt).
Jublia does not fully clear nails in most patients.
The excerpt provides efficacy endpoints but does not support the generalized statement that “in most patients” nails are not fully cleared; the label excerpt does not provide an overall statement phrased that way.
In clinical trials, Jublia had complete cure rates of 15–18% after 48 weeks.
The excerpt indicates Complete Cure is assessed at Week 52 (4 weeks after completion of therapy) and provides 17.8% and 15.2%, not an explicit “15–18% after 48 weeks” phrasing.
In clinical trials, Jublia had mycological cure rates of 53–55% (no detectable fungus) after 48 weeks.
The excerpt defines mycologic cure as negative KOH and negative culture and assesses at Week 52; it does not support “no detectable fungus” phrasing nor “after 48 weeks” phrasing.
In phase 3 trials with 1,170 patients, Jublia applied daily for 48 weeks achieved complete cure (clear nail + no fungus) of 17.8% versus 3.3% with placebo.
The provided excerpt shows Trial 1 JUBLIA N=656 vs Vehicle N=214 with 17.8% vs 3.3% Complete Cure, but does not provide the “phase 3 with 1,170 patients” claim or the composite trial patient count. It also uses endpoint wording not fully supported (“clear nail + no fungus”).
In phase 3 trials, Jublia applied daily for 48 weeks achieved complete or almost complete nail growth of 40–42%.
The excerpt provides Complete or Almost Complete Cure as 26.4% and 23.4% (Trial 1 and Trial 2), not a 40–42% range.
In phase 3 trials, Jublia applied daily for 48 weeks achieved fungus elimination in 53–56% of cases.
The excerpt supports mycologic cure as 55.2% and 53.4%, but does not support the term “fungus elimination” or “after 48 weeks” phrasing.
Results with Jublia vary by infection severity.
The provided excerpt states trial inclusion parameters (20% to 50% clinical involvement; no dermatophytomas; no lunula/matrix involvement) but does not state that outcomes vary by infection severity.
Milder onychomycosis cases respond better to Jublia.
Not supported by any severity-response statement in the provided label excerpt.
Relapse can occur in up to 50% within a year post-treatment with Jublia.
No relapse/incidence data are provided in the excerpt.
Visible changes with Jublia start at 4–8 weeks.
The excerpt does not provide timing of visible changes.
Full effects of Jublia require 48 weeks of daily application to the affected nail and 5 mm under the edge.
The excerpt states cover toenail, folds, bed, hyponychium, and undersurface of the nail plate, but does not specify “5 mm under the edge.”
Nails grow slowly at 1–1.5 mm per month, so cosmetic clearing lags behind fungal kill with Jublia.
The excerpt does not state nail growth rates or a relationship between cosmetic clearing and fungal kill.
Maintenance dosing may be needed for 6–12 months after Jublia treatment.
The excerpt only states once daily for 48 weeks; no maintenance dosing beyond that is described.
Jublia irritation side effects include ingrown nails in 2–3% and redness in 1–2%.
Adverse reactions section is not provided in the excerpt, so specific incidence figures for these events are not supported.
Mild irritation affects 15–20% of patients with Jublia.
No adverse reaction rates are provided in the excerpt.
Jublia is safe for long-term use.
The excerpt does not provide a long-term safety conclusion.
Jublia has no systemic absorption issues.
The excerpt provides pharmacokinetic plasma concentrations (systemic absorption measured), so the absolute “no systemic absorption issues” is not supported.
Jublia should be avoided in patients allergic to azoles.
Contraindications section states “None.” The excerpt does not provide an allergy/azole avoidance contraindication.
Co-existing conditions like diabetes can slow nail growth and may affect Jublia outcomes.
The excerpt does not mention diabetes or comorbidities affecting outcomes.
Contradictions
Low
AI Statement
Jublia should be avoided in patients allergic to azoles.
Label Reference
Contraindications (Section 4): “None.”
Important Omissions
For efficacy endpoints, the label excerpt specifies assessment at Week 52 (4 weeks after completion of therapy) and definitions of Complete Cure, Complete or Almost Complete Cure, and Mycologic Cure (negative KOH and culture).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The AI claims include an unsupported contraindication-allergy statement (claims “avoid azoles allergy” despite label excerpt stating no contraindications) and several unsupported safety/relapse/side-effect incidence claims; these could mislead risk assessment or expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Multiple efficacy and safety claims are unsupported or mis-stated versus the provided label excerpt, including incorrect ranges for “complete or almost complete cure,” unsupported relapse/visible-change timing, and a contraindications-related claim that conflicts with the provided label (“None”).
Suggested Improvement
Limit efficacy statements to the label’s defined endpoints and the provided numeric table values (including Week 52 timing and definitions). Remove or qualify claims not present in the excerpt (relapse rates, visible-change timing, maintenance dosing, specific side-effect rates). Do not state allergy-based avoidance when the provided contraindications section says “None.”